β-glucuronide-linker drug conjugates

Details β-glucuronide-linker drug conjugates β-glucuronide-linker drug conjugates

2006-07-18

2011-10-18

Haq, Shafiqul (Department: 1641)

Chemistry: analytical and immunological testing

Involving an insoluble carrier for immobilizing immunochemicals

Carrier is organic

C530S402000, C530S391900, C436S528000, C436S512000, C436S544000

Reexamination Certificate

active

08039273

ABSTRACT:
Ligand Drug conjugate compounds comprising a β-glucuronide-based linker and methods of using such compounds are provided.

REFERENCES:
patent: 5561119 (1996-10-01), Jacquesy et al.
patent: 5851527 (1998-12-01), Hansen
patent: 6361774 (2002-03-01), Griffiths et al.
patent: 6884869 (2005-04-01), Senter et al.
patent: 6906182 (2005-06-01), Ts'O et al.
patent: WO 03/086312 (2003-10-01), None
patent: WO 2004/010957 (2004-02-01), None
Albin, N. et al., “Main Drug-metabolizing Enzyme Systems in Human Breast Tumors and Peritumoral Tissues,”Cancer Research, Aug. 1, 1993, vol. 53, pp. 3541-3546.
Allen, T.M., “Ligand-Targeted Therapeutics in Anticancer Therapy,”Nature, Oct. 2002, vol. 2, pp. 750-763.
Andrianomenjanahary, S. et al., “Synthesis of Novel Targeted Pro-Prodrugs of Anthracyclines Potentially Activated by a Monoclonal Antibody Galactosidase Conjugate (Part 1),”Bioorganic&Medicinal Chemistry Letters, 1992, vol. 2, No. 9, pp. 1093-1096.
Angenault, S. et al., “Cancer Chemotherapy: A SN-38 (7-Ethyl-10-hydroxycamptothecin) Glucuronide Prodrug for Treatment by a PMT (Prodrug MonoTherapy) Strategy,”Bioorganic&Medicinal Chemistry Letters, 2003, vol. 13, pp. 947-950.
Asai, A. et al., “synthesis and Antitumor Activity of Water-soluble Duocarmycin B1 Prodrugs,”Bioorganic&Medicinal Chemistry Letters, 1999, vol. 9, pp. 2995-2998.
Azoulay, M. et al., “Prodrugs of anthracycline antibiotics suited for tumor-specific activation,”Anti-Cancer Drug Design, 1995, vol. 10, pp. 441-460.
Bakina, E. et al., “Intensely Cytotoxic Anthracycline Prodrugs: Glucuronides,”J. Med. Chem., 1997, vol. 40, No. 25, pp. 4013-4018.
Boons, G-J., ed.,Carbohydrate Chemistry, Blackie Academic & Professional: London, United Kingdom, 1998, pp. 98-174.
Bosslet, K. et al., “Elucidation of the Mechanism Enabling Tumor Selective Prodrug Monotherapy,”Cancer Research, Mar. 15, 1998, vol. 58, pp. 1195-1201.
Bross, P.F. et al., “Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia,”Clinical Cancer Research, Jun. 2001, vol. 7, pp. 1490-1496.
Chen, X. et al., “Glucuronides in Anti-Cancer Therapy,”Curr. Med. Chem.-Anti-Cancer Agents, 2003, vol. 3, No. 2, pp. 139-150.
De Graaf, M. et al., “Beta-Glucuronidase-Mediated Drug Release,”Current Pharmaceutical Design, 2002, vol. 8, No. 15, pp. 1391-1403.
De Graaf, M. et al. “Cytosolic β-glycosidases for activation of glycoside prodrugs of daunorubicin,”Biochemical Pharmacology, 2003, vol. 65, pp. 1875-1881.
De Groot, F.M.H., et al., “Anticancer Prodrugs for Application in Monotherapy: Targeting Hypoxia, Tumor-Associated Enzymes, and Receptors,”Current Medicinal Chemistry, 2001, vol. 8, No. 9, pp. 1093-1122.
Desai, A.A. et al., “UGTpharmcogenomics: implications for cancer risk and cancer therapeutics,”Pharmacogenetics, 2003, vol. 13, No. 8, pp. 517-523.
Drueckhammer, D.G. et al., “Enzyme Catalysis in Synthetic Carbohydrate Chemistry,”Synthesis, Jul. 1991, pp. 499-525.
Dubowchik, G.M. et al., “Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs,”Pharmacology&Therapeutics, 1999, vol. 83, pp. 67-123.
Fuselier, J.A. et al., “An Adjustable Release Rate Linking Strategy for Cytotoxin-Peptide Conjugates,”Bioorganic&Medicinal Chemistry Letters, 2003, vol. 13, pp. 799-803.
Gesson, J.-P. et al., “Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates,”Anti-Cancer Drug Design, 1994, vol. 9, pp. 409-423.
Haisma, H.J. et al., “A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer,”Br. J. Cancer, 1992, vol. 66, pp. 474-478.
Houba, P.H.J. et al., “Characterization of Novel Anthracycline Prodrugs Activated by Human β-glucuronidase for Use in Antibody-Directed Enzyme Prodrug Therapy,”Biochemical Pharmacology, 1996, vol. 52, No. 3, pp. 455-463.
Huang, P.S. et al., “Drug-targeting strategies in cancer therapy,”Current Opinion in Genetics&Development, 2001, vol. 11, pp. 104-110.
Jeffrey, S.C. et al., “Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody-Drug Conjugates,”Bioconjugate Chem., 2006, vol. 17, pp. 831-840.
Kirschke, H., “Lysosomal Cysteine Peptidases and Malignant Tumours,”Cellular Peptidases in Immune Functions and Diseases, Ansorge et al., eds., 1997, Plenum Press, New York, pp. 253-256.
Leenders, R.G.G. et al., “β-Glucuronyl Carbamate Based Pro-moieties Designed for Prodrugs in ADEPT,”Tetrahedron Letters, 1995, vol. 36, No. 10, pp. 1701-1704.
Leenders, R.G.G. et al., “Synthesis and Evaluation of Novel Daunomycin-Phosphate-Sulfate-β-Glucuronide and -β-Glucoside Prodrugs for Application in Adept,”Bioorganic&Medicinal Chemistry Letters, 1995, vol. 5, No. 24, pp. 2975-2960.
Leenders, R.G.G. et al., “Novel Anthracycline-space-β-glucuronide, -β-glucoside, and -β-galactoside Prodrugs for Application in Selective Chemotherapy,”Bioorganic&Medicinal Chemistry, 1999, vol. 7, pp. 1597-1610.
Lougerstay-Madec, R. et al., “Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard,”Anti-Cancer Drug Design, 1998, vol. 13, pp. 995-1007.
Papot, S. et al., “Design of Selectively Activated Anticancer Prodrugs: Elimination and Cyclization Strategies,”Curr. Med. Chem.—Anti-Cancer Agents, 2002, vol. 2, No. 2, pp. 155-185.
Ritter, J.K., “Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions,”Chemico-Biological Interactions, 2000, vol. 129, pp. 171-193.
Schelté, P. et al., “Differential Reactivity of Maleimide and Bromoacetyl Functions with Thiols: Application to the Preparation of Liposomal Diepitope Constructs,”Bioconjugate Chem., 2000, vol. 11, pp. 118-123.
Schmidt, F. et al., “Cancer Chemotherapy: A Paclitaxel Prodrug for ADEPT (Antibody-Directed Enzyme Prodrug Therapy),”Eur. J. Org. Chem., 2001, pp. 2129-2134.
Sperker, B. et al., “The Role of β-Glucuronidase in Drug Disposition and Drug Targeting in Humans,”Clin. Pharmacokinet, Jul. 1997, vol. 33, No. 1, pp. 18-31.
Stachulski, A.V. et al., “The synthesis ofO-glucuronides,”Natural Product Reports, 1998, pp. 173-186.
Toshima, K. et al., “Recent Progress inO-Glycosylation Methods and Its Application to Natural Products Synthesis,”Chemical Reviews, 1993, vol. 93, No. 4, pp. 1503-1531.
Verdier-Pinard, P. et al., “Sustained Intracellular Retention of Dolastatin 10 Causes Its Potent Antimitotic Activity,”Molecular Pharmacology, 2000, vol. 57, pp. 180-187.
Wilbur, D.S. et al., “Biotin Reagents for Antibody Pretargeting. 5. Additional Studies of Biotin Conjugate Design to Provide Biotinidase Stability,”Bioconjugate Chem., 2001, vol. 12, pp. 616-623.
Desbéne, S. et al., “Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation,”Anti-Cancer Dru Design, 1998, vol. 13, pp. 955-968.
Eneyskaya, E.V. et al., “Chemo-enzymatic synthesis of 4-methylumbelliferyl β-(1→4)-D-xylooligosides: new substrates for β-D-xylanease assaus,”Org. Biomol. Chem., 2005, vol. 3, pp. 146-151.
Kelly, M.A. et al., “Preparation of some aryl α-L-arabinofuranosides as substrates for arabinofuranosides,”Carbohydrate Research. 1988, vol. 181, pp. 262-266.
Marino, C. et al., “Synthesis of 4-methylcoumarin-7-yl β-D-galactofuranoside, a fluorogenic substrate for galactofuranosidase,”Carbohydrate Research, 1995, vol. 276, pp. 209-213.
Sanderson et al., “In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconj

Affiliated with

Also associated with

Rating

β-glucuronide-linker drug conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with β-glucuronide-linker drug conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β-glucuronide-linker drug conjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4284216